DelveInsight’s “Advanced Renal Cell Carcinoma Pipeline Insight, 2026” report delivers comprehensive insights into the current clinical development landscape and future growth opportunities within the Advanced Renal Cell Carcinoma market.
The Advanced Renal Cell Carcinoma Pipeline report encompasses thorough commercial and clinical evaluations of pipeline products spanning from pre-clinical development phases through to marketed stages. The report provides detailed drug descriptions, encompassing mechanism of action, clinical trial data, regulatory approvals (where applicable), and product development initiatives including technological advances, partnerships, mergers and acquisitions, funding rounds, regulatory designations, and additional product-specific information.
Key Highlights from the Advanced Renal Cell Carcinoma Pipeline Report:
- Organizations worldwide are actively pursuing the development of innovative Advanced Renal Cell Carcinoma treatment options, achieving notable progress in recent years.
- Leading companies engaged in Advanced Renal Cell Carcinoma therapeutics development include Molecure S.A., Daiichi Sankyo, Janux Therapeutics, NiKang Therapeutics, CoImmune, Infinity Pharmaceuticals, Chia Tai Tianqing Pharmaceutical, Merck Sharp & Dohme, Hoffmann-La Roche, AstraZeneca, Xencor, among others.
- Promising Advanced Renal Cell Carcinoma therapies currently advancing through various clinical trial phases include OATD-02, DS-6000a, JANX008, NKT2152, CMN-001, IPI-549, TQB2450, Belzutifan, Atezolizumab, Volrustomig, XmAb819, and additional candidates anticipated to substantially influence the Advanced Renal Cell Carcinoma market landscape in the forthcoming years.
- In March 2026, Merck & Co., Inc. (operating as MSD beyond the U.S. and Canada) alongside Eisai disclosed preliminary findings from the Phase 3 LITESPARK-011 clinical trial. This investigation assessed a dual oral regimen combining WELIREG® (belzutifan)—Merck’s pioneering HIF-2α inhibitor—with LENVIMA® (lenvatinib), Eisai’s multi-receptor tyrosine kinase inhibitor, for patients with advanced renal cell carcinoma (RCC) experiencing disease progression post anti–PD-1/PD-L1 therapy. Findings were presented as a late-breaking oral session at the ASCO Genitourinary Cancers Symposium 2026 (abstract #LBA417) and highlighted in the official ASCO GU media program.
- In October 2025, Belzutifan (Welireg) combined with lenvatinib (Lenvima) exhibited enhanced progression-free survival (PFS) compared to cabozantinib (Cabometyx) among patients with advanced renal cell carcinoma (RCC) following progression on anti–PD-(L)1 therapy, according to a joint announcement from Merck and Eisai.
- In June 2025, the National Medical Products Administration (NMPA) of China accepted a new drug application (NDA) from Innovent and HUTCHMED for the combination therapy of sintilimab (Tyvyt) with fruquintinib (Elunate) targeting patients with locally advanced or metastatic renal cell carcinoma (RCC) previously treated with one tyrosine kinase inhibitor (TKI).
- In February 2025, refreshed findings from a phase 1 investigation (NCT05122546) shared at the 2025 Genitourinary Cancers Symposium demonstrated that combining CBM588 with cabozantinib (Cabometyx) and nivolumab (Opdivo) improved progression-free survival (PFS) and objective response rate (ORR) in metastatic renal cell carcinoma (mRCC) patients, although it did not produce a substantial increase in Bifidobacterium spp. concentrations.
- In December 2024, during the Society of Urologic Oncology (SUO) annual conference in Dallas, Belzutifan received recognition for its approval across numerous countries, including the United States and Canada, for managing VHL disease-associated neoplasms. Within the U.S., it has also secured approval for adult patients with advanced renal cell carcinoma (RCC) previously treated with a PD-(L)1 inhibitor and a vascular endothelial growth factor-tyrosine kinase inhibitor (VEGF-TKI). Multiple investigations have examined Belzutifan’s application in advanced RCC populations. Dr. Jonasch shared results from a post hoc pooled analysis evaluating Belzutifan’s safety profile in RCC patients receiving 120 mg daily across the LITESPARK-001, LITESPARK-004, LITESPARK-005, and LITESPARK-013 trials.
- In November 2024, Adicet Bio, Inc. (Nasdaq: ACET), a clinical-stage biotechnology company specializing in allogeneic gamma delta T cell therapies for cancer and autoimmune conditions, declared the commencement of patient recruitment for its Phase 1 clinical investigation of ADI-270 in individuals with metastatic or advanced clear cell renal cell carcinoma (ccRCC).
- In September 2024, NiKang Therapeutics® Inc., a clinical-stage biopharmaceutical organization developing novel small molecule oncology therapeutics, revealed that early findings from its ongoing Phase 1/2 clinical study of NKT2152 for advanced clear cell renal cell carcinoma (ccRCC) in previously treated patients would be presented via oral presentation at the European Society for Medical Oncology (ESMO) 2024 Congress.
Advanced Renal Cell Carcinoma Overview
Advanced Renal Cell Carcinoma (RCC) represents a stage of kidney cancer characterized by disease extension beyond the kidney to additional body regions. Renal cell carcinoma develops in the lining of microscopic tubules within the kidney and may advance to later stages when it metastasizes or extends to adjacent lymph nodes or remote organs.
Access a Complimentary Sample PDF Report to learn more about Advanced Renal Cell Carcinoma Pipeline Therapeutic Evaluation:
https://www.delveinsight.com/report-store/advanced-renal-cell-carcinoma-rcc-pipeline-insight
Advanced Renal Cell Carcinoma Drugs Include:
- OATD-02: Molecure S.A.
- DS-6000a: Daiichi Sankyo
- JANX008: Janux Therapeutics
- NKT2152: NiKang Therapeutics
- CMN-001: CoImmune
- IPI-549: Infinity Pharmaceuticals
- TQB2450: Chia Tai Tianqing Pharmaceutical
- Belzutifan: Merck Sharp & Dohme
- Atezolizumab: Hoffmann-La Roche
- Volrustomig: AstraZeneca
- XmAb819: Xencor
Advanced Renal Cell Carcinoma Routes of Administration
The Advanced Renal Cell Carcinoma pipeline report delivers therapeutic evaluation of pipeline drugs organized by Route of Administration. Products are classified under different ROAs including:
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical
Advanced Renal Cell Carcinoma Molecular Classifications
Advanced Renal Cell Carcinoma Products are organized under different Molecule types including:
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
Advanced Renal Cell Carcinoma Pipeline Therapeutic Evaluation
- Advanced Renal Cell Carcinoma Evaluation by Product Type
- Advanced Renal Cell Carcinoma By Development Stage and Product Type
- Advanced Renal Cell Carcinoma Evaluation by Route of Administration
- Advanced Renal Cell Carcinoma By Development Stage and Route of Administration
- Advanced Renal Cell Carcinoma Evaluation by Molecule Type
- Advanced Renal Cell Carcinoma by Development Stage and Molecule Type
DelveInsight’s Advanced Renal Cell Carcinoma Report encompasses approximately 60+ products across different clinical development phases including:
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Additional Advanced Renal Cell Carcinoma product information is available in the report. Download the Advanced Renal Cell Carcinoma pipeline report to discover more about emerging Advanced Renal Cell Carcinoma therapies
Leading Companies in the Advanced Renal Cell Carcinoma Therapeutics Landscape:
Principal companies advancing therapies for Advanced Renal Cell Carcinoma include Merck Sharp & Dohme, Chia Tai Tianqing Pharmaceutical, Hoffmann-La Roche, CoImmune, Infinity Pharmaceuticals, NiKang Therapeutics, Molecure S.A., Daiichi Sankyo, Janux Therapeutics, MedImmune, Eli Lilly and Company, Jiangsu HengRui Medicine Co., Ltd., Allogene Therapeutics, Chongqing Precision Biotech Co., Ltd, Pfizer, Exelixis, BeiGene, Xencor, Teon Therapeutics, Asher Biotherapeutics, Shanghai Junshi Biosciences, Surface Oncology, ProfoundBio, Portage Biotech, Novartis Pharmaceuticals, HiFiBiO, among others.
Advanced Renal Cell Carcinoma Pipeline Evaluation:
The Advanced Renal Cell Carcinoma pipeline report delivers insights into:
- Comprehensive information regarding companies developing therapies for Advanced Renal Cell Carcinoma treatment with aggregated therapies developed per company.
- Assessment of various therapeutic candidates organized into early-stage, mid-stage, and late-stage development for Advanced Renal Cell Carcinoma Treatment.
- Advanced Renal Cell Carcinoma leading companies engaged in targeted therapeutic development with corresponding active and inactive (dormant or discontinued) projects.
- Advanced Renal Cell Carcinoma Drugs under development categorized by development stage, route of administration, target receptor, monotherapy or combination therapy, mechanism of action, and molecular type.
- Comprehensive analysis of partnerships (company-company partnerships and company-academia partnerships), licensing agreements and financial arrangements for future progression of the Advanced Renal Cell Carcinoma market.
The report utilizes data and information obtained from the researcher’s proprietary databases, company/university platforms, clinical trial registries, conferences, SEC documents, investor presentations, and featured press releases from company/university platforms and industry-specific third-party sources.
Download Sample PDF Report to know more about Advanced Renal Cell Carcinoma drugs and therapies
Advanced Renal Cell Carcinoma Pipeline Market Drivers
Rising Prevalence in Advanced Renal Cell Carcinoma, expansion in research and development initiatives are among the critical factors driving the Advanced Renal Cell Carcinoma Market.
Advanced Renal Cell Carcinoma Pipeline Market Barriers
However, adverse effects associated with Advanced Renal Cell Carcinoma treatment, treatment-related costs and additional factors present obstacles to the Advanced Renal Cell Carcinoma Market expansion.
Scope of Advanced Renal Cell Carcinoma Pipeline Insight
- Coverage: Global
- Key Advanced Renal Cell Carcinoma Companies: Molecure S.A., Daiichi Sankyo, Janux Therapeutics, NiKang Therapeutics, CoImmune, Infinity Pharmaceuticals, Chia Tai Tianqing Pharmaceutical, Merck Sharp & Dohme, Hoffmann-La Roche, AstraZeneca, Xencor, among others
- Key Advanced Renal Cell Carcinoma Therapies: OATD-02, DS-6000a, JANX008, NKT2152, CMN-001, IPI-549, TQB2450, Belzutifan, Atezolizumab, Volrustomig, XmAb819, among others
- Advanced Renal Cell Carcinoma Therapeutic Evaluation: Advanced Renal Cell Carcinoma current marketed and Advanced Renal Cell Carcinoma emerging therapies
- Advanced Renal Cell Carcinoma Market Dynamics: Advanced Renal Cell Carcinoma market catalysts and Advanced Renal Cell Carcinoma market challenges
Request a Sample PDF Report for Advanced Renal Cell Carcinoma Pipeline Assessment and Clinical Trials.
Table of Contents
- Advanced Renal Cell Carcinoma Report Introduction
- Advanced Renal Cell Carcinoma Executive Summary
- Advanced Renal Cell Carcinoma Overview
- Advanced Renal Cell Carcinoma – Analytical Perspective In-depth Commercial Assessment
- Advanced Renal Cell Carcinoma Pipeline Therapeutics
- Advanced Renal Cell Carcinoma Late Stage Products (Phase II/III)
- Advanced Renal Cell Carcinoma Mid Stage Products (Phase II)
- Advanced Renal Cell Carcinoma Early Stage Products (Phase I)
- Advanced Renal Cell Carcinoma Preclinical Stage Products
- Advanced Renal Cell Carcinoma Therapeutics Assessment
- Advanced Renal Cell Carcinoma Inactive Products
- Company-University Collaborations (Licensing/Partnering) Analysis
- Advanced Renal Cell Carcinoma Key Companies
- Advanced Renal Cell Carcinoma Key Products
- Advanced Renal Cell Carcinoma Unmet Needs
- Advanced Renal Cell Carcinoma Market Drivers and Barriers
- Advanced Renal Cell Carcinoma Future Perspectives and Conclusion
- Advanced Renal Cell Carcinoma Analyst Views
- Appendix
- About DelveInsight
About DelveInsight
DelveInsight is a premier Business Consultant and Market Research organization specializing exclusively in life sciences. It supports pharmaceutical companies by delivering comprehensive end-to-end solutions to optimize their performance. It also provides Healthcare Consulting Services, which assist in market analysis to accelerate business growth and address challenges with a pragmatic approach.
Contact Us
Kanishk
